tiprankstipranks
Trending News
More News >
Novo Nordisk (GB:0QIU)
LSE:0QIU
UK Market
Advertisement

Novo Nordisk (0QIU) Share Forecast & Price Target

Compare
65 Followers
See the Price Targets and Ratings of:

0QIU Analyst Ratings

Hold
14Ratings
Hold
4 Buy
9 Hold
1 Sell
Based on 14 analysts giving stock ratings to
Novo
Nordisk
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0QIU Stock 12 Month Forecast

Average Price Target

kr468.62
▲(28.28% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is kr468.62 with a high forecast of kr620.00 and a low forecast of kr340.00. The average price target represents a 28.28% change from the last price of kr365.31.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"299":"kr299","900":"kr900","449.25":"kr449.3","599.5":"kr599.5","749.75":"kr749.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":620,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr620.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":468.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr468.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":340,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr340.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[299,449.25,599.5,749.75,900],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,300.16,324.76307692307694,349.36615384615385,373.96923076923076,398.57230769230773,423.1753846153846,447.77846153846156,472.38153846153847,496.9846153846154,521.5876923076924,546.1907692307692,570.7938461538461,595.396923076923,{"y":620,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,300.16,313.1184615384616,326.0769230769231,339.03538461538466,351.99384615384616,364.9523076923077,377.91076923076923,390.8692307692308,403.8276923076923,416.78615384615387,429.7446153846154,442.70307692307694,455.6615384615385,{"y":468.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,300.16,303.2246153846154,306.2892307692308,309.3538461538462,312.41846153846154,315.48307692307696,318.54769230769233,321.6123076923077,324.67692307692306,327.7415384615385,330.80615384615385,333.8707692307692,336.93538461538463,{"y":340,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":886.89,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":899.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":776,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":748.63,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":746.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":604.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":594.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":623.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475.89,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":426.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":427.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr620.00Average Price Targetkr468.62Lowest Price Targetkr340.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
DBS
kr340
Hold
-6.93%
Downside
Upgraded
08/22/25
Novo Nordisk upgraded to Hold from Sell at DBS BankNovo Nordisk upgraded to Hold from Sell at DBS Bank
Kepler Capital  Analyst forecast on GB:0QIU
Kepler Capital
Kepler Capital
kr630kr510
Buy
39.61%
Upside
Reiterated
08/22/25
Kepler Capital Sticks to Their Buy Rating for Novo Nordisk (0QIU)
Deutsche Bank  Analyst forecast on GB:0QIU
Deutsche Bank
Deutsche Bank
kr600
Buy
64.24%
Upside
Reiterated
08/21/25
Novo Nordisk (0QIU) Gets a Buy from Deutsche Bank
UBS
kr340
Hold
-6.93%
Downside
Reiterated
08/18/25
UBS Sticks to Its Hold Rating for Novo Nordisk (0QIU)
Bernstein
kr620
Hold
69.72%
Upside
Reiterated
08/11/25
Bernstein Reaffirms Their Hold Rating on Novo Nordisk (0QIU)
DZ BANK AG Analyst forecast on GB:0QIU
DZ BANK AG
DZ BANK AG
Hold
Reiterated
08/08/25
DZ BANK AG Keeps Their Hold Rating on Novo Nordisk (0QIU)
Goldman Sachs Analyst forecast on GB:0QIU
Goldman Sachs
Goldman Sachs
kr400kr392
Buy
7.31%
Upside
Reiterated
08/08/25
Novo Nordisk (0QIU) Gets a Buy from Goldman Sachs
J.P. Morgan Analyst forecast on GB:0QIU
J.P. Morgan
J.P. Morgan
kr500
Buy
36.87%
Upside
Reiterated
08/06/25
J.P. Morgan Sticks to Its Buy Rating for Novo Nordisk (0QIU)
Bank of America Securities Analyst forecast on GB:0QIU
Bank of America Securities
Bank of America Securities
kr375
Hold
2.65%
Upside
Reiterated
08/06/25
Cautious Hold Rating on Novo Nordisk Amid Profit Warning and Legal Challenges
Jefferies
kr415
Sell
13.60%
Upside
Reiterated
08/06/25
Jefferies Sticks to Their Sell Rating for Novo Nordisk (0QIU)
Barclays Analyst forecast on GB:0QIU
Barclays
Barclays
kr375
Hold
2.65%
Upside
Reiterated
08/04/25
Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)
Oddo BHF
kr465
Hold
27.29%
Upside
Downgraded
07/30/25
Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF
Berenberg Bank Analyst forecast on GB:0QIU
Berenberg Bank
Berenberg Bank
kr610
Hold
66.98%
Upside
Reiterated
07/15/25
Berenberg Bank Remains a Hold on Novo Nordisk (0QIU)
Morgan Stanley Analyst forecast on GB:0QIU
Morgan Stanley
Morgan Stanley
kr550
Hold
50.56%
Upside
Reiterated
06/23/25
Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)
Stifel Nicolaus Analyst forecast on GB:0QIU
Stifel Nicolaus
Stifel Nicolaus
kr780kr700
Hold
91.62%
Upside
Downgraded
03/03/25
Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
DBS
kr340
Hold
-6.93%
Downside
Upgraded
08/22/25
Novo Nordisk upgraded to Hold from Sell at DBS BankNovo Nordisk upgraded to Hold from Sell at DBS Bank
Kepler Capital  Analyst forecast on GB:0QIU
Kepler Capital
Kepler Capital
kr630kr510
Buy
39.61%
Upside
Reiterated
08/22/25
Kepler Capital Sticks to Their Buy Rating for Novo Nordisk (0QIU)
Deutsche Bank  Analyst forecast on GB:0QIU
Deutsche Bank
Deutsche Bank
kr600
Buy
64.24%
Upside
Reiterated
08/21/25
Novo Nordisk (0QIU) Gets a Buy from Deutsche Bank
UBS
kr340
Hold
-6.93%
Downside
Reiterated
08/18/25
UBS Sticks to Its Hold Rating for Novo Nordisk (0QIU)
Bernstein
kr620
Hold
69.72%
Upside
Reiterated
08/11/25
Bernstein Reaffirms Their Hold Rating on Novo Nordisk (0QIU)
DZ BANK AG Analyst forecast on GB:0QIU
DZ BANK AG
DZ BANK AG
Hold
Reiterated
08/08/25
DZ BANK AG Keeps Their Hold Rating on Novo Nordisk (0QIU)
Goldman Sachs Analyst forecast on GB:0QIU
Goldman Sachs
Goldman Sachs
kr400kr392
Buy
7.31%
Upside
Reiterated
08/08/25
Novo Nordisk (0QIU) Gets a Buy from Goldman Sachs
J.P. Morgan Analyst forecast on GB:0QIU
J.P. Morgan
J.P. Morgan
kr500
Buy
36.87%
Upside
Reiterated
08/06/25
J.P. Morgan Sticks to Its Buy Rating for Novo Nordisk (0QIU)
Bank of America Securities Analyst forecast on GB:0QIU
Bank of America Securities
Bank of America Securities
kr375
Hold
2.65%
Upside
Reiterated
08/06/25
Cautious Hold Rating on Novo Nordisk Amid Profit Warning and Legal Challenges
Jefferies
kr415
Sell
13.60%
Upside
Reiterated
08/06/25
Jefferies Sticks to Their Sell Rating for Novo Nordisk (0QIU)
Barclays Analyst forecast on GB:0QIU
Barclays
Barclays
kr375
Hold
2.65%
Upside
Reiterated
08/04/25
Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)
Oddo BHF
kr465
Hold
27.29%
Upside
Downgraded
07/30/25
Novo Nordisk downgraded to Neutral from Outperform at Oddo BHFNovo Nordisk downgraded to Neutral from Outperform at Oddo BHF
Berenberg Bank Analyst forecast on GB:0QIU
Berenberg Bank
Berenberg Bank
kr610
Hold
66.98%
Upside
Reiterated
07/15/25
Berenberg Bank Remains a Hold on Novo Nordisk (0QIU)
Morgan Stanley Analyst forecast on GB:0QIU
Morgan Stanley
Morgan Stanley
kr550
Hold
50.56%
Upside
Reiterated
06/23/25
Morgan Stanley Reaffirms Their Hold Rating on Novo Nordisk (0QIU)
Stifel Nicolaus Analyst forecast on GB:0QIU
Stifel Nicolaus
Stifel Nicolaus
kr780kr700
Hold
91.62%
Upside
Downgraded
03/03/25
Novo Nordisk downgraded to Hold from Buy at StifelNovo Nordisk downgraded to Hold from Buy at Stifel
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

1 Month
xxx
Success Rate
37/60 ratings generated profit
62%
Average Return
+1.57%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.67% of your transactions generating a profit, with an average return of +1.57% per trade.
3 Months
xxx
Success Rate
38/60 ratings generated profit
63%
Average Return
+2.95%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.33% of your transactions generating a profit, with an average return of +2.95% per trade.
1 Year
Richard VosserJ.P. Morgan
Success Rate
43/60 ratings generated profit
72%
Average Return
+17.53%
reiterated a buy rating 22 days ago
Copying Richard Vosser's trades and holding each position for 1 Year would result in 71.67% of your transactions generating a profit, with an average return of +17.53% per trade.
2 Years
xxx
Success Rate
35/60 ratings generated profit
58%
Average Return
+17.84%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 58.33% of your transactions generating a profit, with an average return of +17.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QIU Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
21
24
24
17
13
Buy
6
3
5
8
10
Hold
15
13
10
13
18
Sell
5
5
5
2
2
Strong Sell
0
0
0
0
0
total
47
45
44
40
43
In the current month, 0QIU has received 23 Buy Ratings, 18 Hold Ratings, and 2 Sell Ratings. 0QIU average Analyst price target in the past 3 months is 468.62.
Each month's total comprises the sum of three months' worth of ratings.

0QIU Financial Forecast

0QIU Earnings Forecast

Next quarter’s earnings estimate for 0QIU is kr6.05 with a range of kr5.66 to kr6.50. The previous quarter’s EPS was kr5.96. 0QIU beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.93% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.
Next quarter’s earnings estimate for 0QIU is kr6.05 with a range of kr5.66 to kr6.50. The previous quarter’s EPS was kr5.96. 0QIU beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.93% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.

0QIU Sales Forecast

Next quarter’s sales forecast for 0QIU is kr77.32B with a range of kr74.03B to kr82.98B. The previous quarter’s sales results were kr76.86B. 0QIU beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.94% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.
Next quarter’s sales forecast for 0QIU is kr77.32B with a range of kr74.03B to kr82.98B. The previous quarter’s sales results were kr76.86B. 0QIU beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.94% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.

0QIU Stock Forecast FAQ

What is GB:0QIU’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is 468.62.
    What is GB:0QIU’s upside potential, based on the analysts’ average price target?
    Novo Nordisk has 28.28% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Novo Nordisk a Buy, Sell or Hold?
          Novo Nordisk has a consensus rating of Hold, which is based on 4 buy ratings, 9 hold ratings and 1 sell ratings.
            What is Novo Nordisk’s share price target?
            The average share price target for Novo Nordisk is 468.62. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is kr620.00 ,and the lowest forecast is kr340.00. The average share price target represents 28.28% Increase from the current price of kr365.31.
              What do analysts say about Novo Nordisk?
              Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of Novo Nordisk?
                To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis